Harvard Bioscience Inc (HBIO)vsEli Lilly and Company (LLY)
HBIO
Harvard Bioscience Inc
$6.20
-4.40%
HEALTHCARE · Cap: $27.94M
LLY
Eli Lilly and Company
$1,131.42
-0.32%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 84371% more annual revenue ($72.25B vs $85.53M). LLY leads profitability with a 35.0% profit margin vs -11.4%. HBIO appears more attractively valued with a PEG of 1.31. LLY earns a higher WallStSmart Score of 78/100 (B+).
HBIO
Avoid35
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Revenue declined 4.7%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HBIO
The strongest argument for HBIO centers on Price/Book. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 4.39 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
HBIO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
HBIO carries more volatility with a beta of 1.51 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?